Cassava Sciences Inc (NASDAQ:SAVA)
| 30.92 Delayed Data As of Feb 03 |  -0.02 / -0.06%Today’s Change | 13.84 Today|||52-Week Range 62.49 | +4.67% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $1.3B |
Company Description
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
Contact Information
Cassava Sciences, Inc. 6801 North Capital of Texas Highway Austin Texas 78731 |
Employees
Shareholders
| Individual stakeholders | 6.12% |
| Mutual fund holders | 15.25% |
| Other institutional | 11.36% |
Top Executives
| Remi Barbier | Chairman, President & Chief Executive Officer |
| Eric J. Schoen | Chief Financial Officer |
| James W. Kupiec | Chief Medical Officer |
| Michael Zamloot | Senior Vice President-Technical Operations |
| George B. Thornton | Senior Vice President-Technology |
